Minerva Neurosciences Files 2024 10-K Amendment

Ticker: NERV · Form: 10-K/A · Filed: Apr 29, 2025 · CIK: 1598646

Sentiment: neutral

Topics: amendment, annual-report, pharmaceutical

TL;DR

Minerva Neurosciences filed an amendment to its 2024 10-K, check for updates on their financials.

AI Summary

Minerva Neurosciences, Inc. filed an amendment (No. 2) to its 2024 10-K report on April 29, 2025. The company, incorporated in Delaware with its principal executive offices in Burlington, MA, operates in the pharmaceutical preparations sector. This amendment pertains to the fiscal year ended December 31, 2024.

Why It Matters

This filing provides updated information for the fiscal year 2024, which is crucial for investors and stakeholders to assess the company's financial health and strategic direction.

Risk Assessment

Risk Level: low — This is a routine amendment to a previously filed annual report, not indicating new or elevated risks.

Key Numbers

Key Players & Entities

FAQ

What is the purpose of this 10-K/A filing?

This is Amendment No. 2 to the annual report for the fiscal year ended December 31, 2024, filed to provide updated information.

What is the company's full legal name and state of incorporation?

The company's full legal name is Minerva Neurosciences, Inc., and it is incorporated in Delaware.

Where are Minerva Neurosciences, Inc.'s principal executive offices located?

The principal executive offices are located at 1500 District Avenue, Burlington, MA 01803.

What is the SEC file number for Minerva Neurosciences, Inc.?

The SEC file number is 001-36517.

What industry does Minerva Neurosciences, Inc. operate in?

Minerva Neurosciences, Inc. operates in the Pharmaceutical Preparations sector, with SIC code 2834.

Filing Details

This Form 10-K/A (Form 10-K/A) was filed with the SEC on April 29, 2025 regarding Minerva Neurosciences, Inc. (NERV).

View full filing on EDGAR

View Full Filing

View this 10-K/A filing on SEC EDGAR

View on Read The Filing